Quantcast
Channel: BioTuesdays » Mark Sirgo
Browsing all 2 articles
Browse latest View live

Image may be NSFW.
Clik here to view.

BioDelivery on track for mid-year NDA filing

BioDelivery Sciences (NASDAQ:BDSI) is on track to file a new drug application with the FDA this summer for its Bunavail treatment for opioid dependence, one of two Phase 3 candidates in its product...

View Article



Image may be NSFW.
Clik here to view.

BioDelivery posts disappointing Clonidine trial results

Shares of BioDelivery Sciences International (NASDAQ:BDSI) lost more than a quarter of their market value at the mid-session on Monday after the company announced disappointing Phase 3 trial results...

View Article
Browsing all 2 articles
Browse latest View live




Latest Images